The effect of sodium zirconium cyclosilicate is being investigated on arrhythmia-related cardiovascular outcomes in patients on chronic hemodialysis with recurrent hyperkalemia in the ongoing phase 3 DIALIZE-Outcomes study.
No benefit seen vs valsartan for reducing NT-proBNP levels for patients with chronic advanced heart failure and reduced ejection fraction
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
Lower odds of return to spontaneous circulation, survival to hospital discharge per minute later epinephrine administration
The EMPEROR-Preserved trial compared the efficacy and safety of empagliflozin with placebo in adults with heart failure and preserved ejection fraction, with and without diabetes.
Majority of cases (88.3%) seen in women, especially those aged 50 years or older; incidence higher in middle-aged men than younger men
The new packaging allows for ease of administration and convenience.
The analysis included 49,357 patients undergoing LAAO procedures with the Watchman Left Atrial Appendage Closure device.
Benefits for heart failure patients include functional capacity and fewer complications with newer devices
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
